Design and Exploration of Novel Boronic Acid Inhibitors Reveals Important Interactions with a Clavulanic Acid-Resistant Sulfhydryl-Variable (SHV) β-Lactamase

Journal of Medicinal Chemistry
2013.0

Abstract

Inhibitor resistant (IR) class A β-lactamases pose a significant threat to many current antibiotic combinations. The K234R substitution in the SHV β-lactamase, from Klebsiella pneumoniae , results in resistance to ampicillin/clavulanate. After site-saturation mutagenesis of Lys-234 in SHV, microbiological and biochemical characterization of the resulting β-lactamases revealed that only -Arg conferred resistance to ampicillin/clavulanate. X-ray crystallography revealed two conformations of Arg-234 and Ser-130 in SHV K234R. The movement of Ser-130 is the principal cause of the observed clavulanate resistance. A panel of boronic acid inhibitors was designed and tested against SHV-1 and SHV K234R. A chiral ampicillin analogue was discovered to have a 2.4 ± 0.2 nM K(i) for SHV K234R; the chiral ampicillin analogue formed a more complex hydrogen-bonding network in SHV K234R vs SHV-1. Consideration of the spatial position of Ser-130 and Lys-234 and this hydrogen-bonding network will be important in the design of novel antibiotics targeting IR β-lactamases.

Knowledge Graph

Similar Paper

Design and Exploration of Novel Boronic Acid Inhibitors Reveals Important Interactions with a Clavulanic Acid-Resistant Sulfhydryl-Variable (SHV) β-Lactamase
Journal of Medicinal Chemistry 2013.0
The Lys234Arg Substitution in the Enzyme SHV-72 Is a Determinant for Resistance to Clavulanic Acid Inhibition
Antimicrobial Agents and Chemotherapy 2008.0
Molecular and Biochemical Characterization of SHV-56, a Novel Inhibitor-Resistant β-Lactamase fromKlebsiella pneumoniae
Antimicrobial Agents and Chemotherapy 2008.0
Biochemical Study of a New Inhibitor-Resistant β-Lactamase, SHV-84, Produced by a Clinical Escherichia coli Strain
Antimicrobial Agents and Chemotherapy 2010.0
Structure-based optimization of cephalothin-analogue boronic acids as β-lactamase inhibitors
Bioorganic & Medicinal Chemistry 2008.0
Homology modeling and docking study of recent SHV type β-lactamses with traditional and novel inhibitors: an in silico approach to combat problem of multiple drug resistance in various infections
Medicinal Chemistry Research 2012.0
Substrate Selectivity and a Novel Role in Inhibitor Discrimination by Residue 237 in the KPC-2 β-Lactamase
Antimicrobial Agents and Chemotherapy 2010.0
Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance
European Journal of Medicinal Chemistry 2022.0
Clavulanic Acid: a Beta-Lactamase-Inhibiting Beta-Lactam from <i>Streptomyces clavuligerus</i>
Antimicrobial Agents and Chemotherapy 1977.0
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
Journal of Medicinal Chemistry 2015.0